Literature DB >> 17387192

Oral sildenafil to control pulmonary hypertension after congenital heart surgery.

Farah Peiravian1, Ahmad A Amirghofran, Mohammad Borzouee, Gholam H Ajami, Mohammad R Sabri, Sara Kolaee.   

Abstract

This study investigates the role of oral sildenafil in decreasing pulmonary pressure after congenital heart surgery. Between September 2002 and September 2004, among a group of postoperative children with large septal defects, moderate to severe pulmonary hypertension [pulmonary artery (PA) to aortic (Ao) pressure ratio of 0.76 +/- 0.17] and systemic desaturation (Ao Sat = 0.89 +/- 0.11), oral sildenafil (0.3 mg x kg(-1), every 3 hours) was administered for a period of 24-48 hours (sildenafil group). These patients were compared to a group of 22 children with similar pathologies who did not receive sildenafil (control group). Postoperative PA pressure (28.61 +/- 7.80 vs 39.40 +/- 10.80 mm Hg) and PA/Ao pressure (0.28 +/- 0.08 vs 0.41 +/- 0.11) were significantly lower in the sildenafil group ( p = 0.001 and 0.001 respectively). Pulmonary hypertensive crisis was detected in 4 patients in the control group, but none in the sildenafil group ( p = 0.02). There was no significant rise in PA pressure following discontinuation of the drug (26.30 +/- 6.66 vs 28.49 +/- 10.93 mm Hg, p = 0.366). No significant complications were noticed regarding sildenafil use. Low doses of oral sildenafil appear to be effective and safe to control postoperative PA pressure in children. Absence of rebound pulmonary hypertension, availability, and low cost of the drug are considered as its major advantages.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17387192     DOI: 10.1177/021849230701500207

Source DB:  PubMed          Journal:  Asian Cardiovasc Thorac Ann        ISSN: 0218-4923


  14 in total

1.  Sildenafil therapy for pulmonary hypertension before and after pediatric congenital heart surgery.

Authors:  Gaetano Palma; Raffaele Giordano; Veronica Russolillo; Sabato Cioffi; Sergio Palumbo; Marco Mucerino; Vincenzo Poli; Carlo Vosa
Journal:  Tex Heart Inst J       Date:  2011

Review 2.  Advances in diagnosis and treatment of pulmonary arterial hypertension in neonates and children with congenital heart disease.

Authors:  Monnipa Suesaowalak; John P Cleary; Anthony C Chang
Journal:  World J Pediatr       Date:  2010-02-09       Impact factor: 2.764

Review 3.  Pharmacologic management of perioperative pulmonary hypertension.

Authors:  Julie W Cheng; Adriano R Tonelli; Gosta Pettersson; Richard A Krasuski
Journal:  J Cardiovasc Pharmacol       Date:  2014-04       Impact factor: 3.105

4.  Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial.

Authors:  David J Goldberg; Benjamin French; Michael G McBride; Bradley S Marino; Nicole Mirarchi; Brian D Hanna; Gil Wernovsky; Stephen M Paridon; Jack Rychik
Journal:  Circulation       Date:  2011-03-07       Impact factor: 29.690

5.  Pharmacokinetics of sildenafil in children with pulmonary arterial hypertension.

Authors:  Hugo Juárez Olguín; Hector Osnaya Martínez; Carmen Flores Pérez; Blanca Ramírez Mendiola; Liliana Rivera Espinosa; Juan Luis Chávez Pacheco; Janett Flores Pérez; Ignacio Mora Magaña
Journal:  World J Pediatr       Date:  2017-08-08       Impact factor: 2.764

6.  Postoperative use of oral sildenafil in pediatric patients with congenital heart disease.

Authors:  Ju Yeon Uhm; Won-Kyoung Jhang; Jeong-Jun Park; Dong-Man Seo; Sung-Cheol Yun; Tae-Jin Yun
Journal:  Pediatr Cardiol       Date:  2010-01-07       Impact factor: 1.655

7.  Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?

Authors:  Peter Steele; Geoff Strange; John Wlodarczyk; Brad Dalton; Simon Stewart; Eli Gabbay; Anne Keogh
Journal:  BMC Cardiovasc Disord       Date:  2010-02-22       Impact factor: 2.298

Review 8.  Sildenafil for the treatment of pulmonary hypertension in pediatric patients.

Authors:  Alice J Huddleston; Chad A Knoderer; Jennifer L Morris; Eric S Ebenroth
Journal:  Pediatr Cardiol       Date:  2009-08-25       Impact factor: 1.655

9.  Perioperative sildenafil therapy for pulmonary hypertension in infants undergoing congenital cardiac defect closure.

Authors:  Ashraf A H El Midany; Ezzeldin A Mostafa; Sherif Azab; Ghada A Hassan
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-08-28

10.  Additive effect of phosphodiesterase inhibitors in control of pulmonary hypertension after congenital cardiac surgery in children.

Authors:  Peiravian Farah; Amirghofran Ahmad-Ali; Ghamsari Hanane; Emaminia Abbas
Journal:  Iran J Pediatr       Date:  2013-02       Impact factor: 0.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.